참고문헌
- Cetin I, Topcul M (2014). Triple negative breast cancer. Asian Pac J Cancer Prev, 15, 2427-31. https://doi.org/10.7314/APJCP.2014.15.6.2427
- Dawood S, Broglio K, Kau SW, et al (2009). Triple receptornegative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol, 27, 220-6. https://doi.org/10.1200/JCO.2008.17.9952
- Demicheli R, Bonadonna G, Hrushesky WJ, et al (2004). Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour. Breast Cancer Res, 6, 689-96. https://doi.org/10.1186/bcr937
- Fisher B, Brown AM, Dimitrov NV, et al (1990). Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifennonresponsive tumors: results from the National Surgical adjuvant Breast and Bowel Project B-15. J Clin Oncol, 8, 1483-96. https://doi.org/10.1200/JCO.1990.8.9.1483
- Foulkes WD, Smith IE, Reis-Filho JS (2010). Triple-negative breast cancer. N Engl J Med, 363, 1938-48. https://doi.org/10.1056/NEJMra1001389
- Hudis CA, Gianni L (2011). Triple-negative breast cancer: an unmet medical need. Oncol, 16, 1-11.
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, 457-81. https://doi.org/10.1080/01621459.1958.10501452
- Keam B, Im SA, Kim HJ, et al (2007). Prognostic impact of clinicopathological parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer, 7, 203. https://doi.org/10.1186/1471-2407-7-203
- Kong M, Hong SE (2013). Which patients might benefit from postmastectomy radiotherapy in breast cancer patients with t1-2 tumor and 1-3 axillary lymph nodes metastasis? Cancer Res Treat, 45, 103-11. https://doi.org/10.4143/crt.2013.45.2.103
- Krishnamurthy S, Poornima R, Challa VR, et al (2012). Triple negative breast cancer - our experience and review. Indian J Surg Oncol, 3, 12-6. https://doi.org/10.1007/s13193-012-0138-2
- Li CY, Zhang S, Zhang XB, et al (2013). Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study. Asian Pac J Cancer Prev, 14, 3779-84. https://doi.org/10.7314/APJCP.2013.14.6.3779
- Liedke C, Mazouni C, Hess KR, et al (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 26, 1275-81. https://doi.org/10.1200/JCO.2007.14.4147
- Malorni L, Shetty PB, De Angelis C, et al (2012). Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat, 136, 795-804. https://doi.org/10.1007/s10549-012-2315-y
- Ovcaricek T, Frkovic SG, Matos E, et al (2011). Triple negative breast cancer - prognostic factors and survival. Radiol Oncol, 45, 46-52.
- Quiet CA, Ferguson DJ, Weichselbaum RR, et al (1995). Natural history of node negative breast cancer, a study of 826 patients with long term follow up. J Clin Oncol, 13, 1144-51. https://doi.org/10.1200/JCO.1995.13.5.1144
- Rhee J, Han SW, Oh DY, et al (2008). The clinicopathologic characteristics and prognostic significance of triplenegativity in node-negative breast cancer. BMC Cancer, 8, 307. https://doi.org/10.1186/1471-2407-8-307
- Roche H, Fumoleau P, Spielmann M, et al (2006). Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol, 24, 5664-71. https://doi.org/10.1200/JCO.2006.07.3916
- Sen S, Gayen R, Das S, et al (2012). A clinical and pathological study of triple negative breast carcinoma: experience of a tertiary care centre in eastern India. J Indian Med Assoc, 110, 686-9.
- Sharma B, Satyanarayan, Kalwar A, et al (2013). Five year retrospective survival analysis of triple negative breast cancer in North-West India. Indian J Cancer, 50, 330-2. https://doi.org/10.4103/0019-509X.123616
- Suresh P, Batra U, Doval DC (2013). Epidemiological and clinical profile of triple negative breast cancer at a cancer hospital in North India. Indian J Med Paediatr Oncol, 34, 89-95. https://doi.org/10.4103/0971-5851.116185
- Tian XS, Cong MH, Zhou WH, et al (2008). Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Onkologie, 31, 610-4.
- Wolff AC, Hammond ME, Schwartz JN, et al (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45.